Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Andrea Newkirk
Period: Reporting periods mapped to calendar 2024 Q4 – 2025 Q3 (4 quarters).
- Questions
- 5on tracked calls
- Challenge rate
- 0%none of 5 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 4with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 5 of 5 questions from 1 company
INSMInsmed Incorporated5 questions · 4 reporting periods · 0 of 5 challenging
Calendar 2025 Q3
what types of investments are needed to prepare for commercialization, maybe particularly with respect to your sales force infrastructure
Show response
CEO indicated cautious European investment approach pending reimbursement clarity. Japan sales force already expanded for ARIKAYCE. CFO declined quarter-by-quarter BRINSUPRI gross-to-net but reiterated 25%-35% analog at launch remains reasonable.
Calendar 2025 Q2
how are you thinking about the potential for treprostinil to demonstrate an antifibrotic effect there? And what could that then imply for TPIP?
Show response
CMO indicated TPIP could potentially have stronger effects than TETON results given its profile. Could move directly to Phase 3 in IPF if TETON positive.
Calendar 2025 Q1
how much does potential MFN legislation factor into your thinking on how to price both in the U.S. and abroad?
Show response
CEO emphasized flexibility in setting prices sequentially across U.S., Europe, U.K., Japan. ARIKAYCE was priced at parity across regions.
can you speak to what trends, if any, that you're picking up on? And when you think about this patient group, how motivated are they to actively seek out
Show response
Management noted favorable backdrop but acknowledged uncertainty on whether launch will see bolus or gradual ramp. Reached nearly 30,000 physicians.
Calendar 2024 Q4
if you could frame for us what you would be considering clinically and commercially meaningful
Show response
CEO framed prostacyclin class PVR reductions at low teens to low 20s. Anything above high end would be best-in-class. Phase 3 ILD awaiting single capsule formulation work.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| INSM Insmed Incorporated | 5 | 0%none of 5 questions |
- INSMInsmed Incorporated · 5 questions0%none of 5 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | 2 | 0%none of 2 questions | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Pricing2
- Innovation & R&D2
- Product Launch2
- Geographic Expansion1
- Competitive Dynamics1
- Regulation Policy1
- Demand1